DF1001 for Solid Cancers
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new treatment called DF1001-001 that helps the immune system target and destroy cancer cells. It focuses on patients with certain types of cancers that have a protein called HER2. The treatment works by activating immune cells to recognize and attack these cancer cells.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot be on any concurrent anticancer treatments or certain other therapies, so it's best to discuss your specific medications with the trial team.
Are You a Good Fit for This Trial?
Adults with various advanced solid tumors, especially those expressing HER2. Participants must have measurable disease and adequate organ function, and women of childbearing age must use effective contraception. Excluded are individuals with recent other cancers, CNS metastases, severe heart conditions, uncontrolled infections or allergies to monoclonal antibodies.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive increasing doses of DF1001 to determine the maximum tolerated dose
Dose Expansion
Participants receive the recommended phase 2 dose (RP2D) of DF1001, either as monotherapy or in combination with other drugs
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- DF1001
- Nab paclitaxel
- Nivolumab
DF1001 is already approved in United States for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dragonfly Therapeutics
Lead Sponsor